Thursday 7 May, 2026
Objectives: The continued spread of antimicrobial resistance demands an antibiotic development paradigm that explicitly accounts for the host immune response….
Read moreAbstracts
MULTIDIMENSIONAL SCALING FOR LONGITUDINAL DATA EMBEDDINGS IN PHARMACOMETRICS
Thursday 7 May, 2026
Introduction/Objectives: Longitudinal data in pharmacometrics typically involves multiple time-varying inputs and outputs for each subject in a population. Each subject…
Read moreDEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGUATE WITH REZETECAN PAYLOAD IN MICE
Thursday 7 May, 2026
Introduction A quantitative understanding of the whole-body pharmacokinetics (PK) of antibody-drug conjugates (ADCs) is essential for establishing the exposure-response relationship…
Read moreModeling the stochasticity of bacterial resistance emergence to bacteriophages
Thursday 7 May, 2026
Objectives: Drug resistance may emerge through pressure exerted by antimicrobial treatments [1], which sometimes lead to acquisition of resistance and…
Read moreCharacterization of real-world pembrolizumab population pharmacokinetics in cancer patients: towards identification of non-responders using change in clearance as efficacy biomarker and individualization of the dosing interval
Thursday 7 May, 2026
Background: The approved dose of pembrolizumab was established in phase I-III clinical studies with 2 mg/kg every three weeks (Q3W)…
Read moreMechanistic–Latent Class Modeling to Improve Response Classification in «Mouse Clinical Trials»
Thursday 7 May, 2026
Introduction: In oncology, high rates of therapeutic failure (particularly in late stages of clinical development) highlight the need to improve…
Read moreBiomarker-Guided Dose Selection Facilitated by a C-Peptide Model in Type 1 Diabetes Patients
Thursday 7 May, 2026
Introduction There is no approved disease-modifying therapy for new-onset Type 1 Diabetes (NOT1D). Although rabbit anti-thymocyte globulin (rATG) is effective…
Read morePopulation Pharmacokinetic-Pharmacodynamic Modelling of Ciprofol in Chinese Elderly Patients Undergoing Orthopedic Surgery
Thursday 7 May, 2026
Introduction: Ciprofol is a novel γ-aminobutyric acid type A (GABA A) receptor agonist with 4–5 fold greater potency than propofol…
Read moreCROSS-PRODUCT POPULATION PHARMACOKINETIC MODELING OF HAEMOGLOBIN S POLYMERIZATION INHIBITORS TO OPTIMISE PAEDIATRIC PK STUDY DESIGN USING STOCHASTIC SIMULATION-ESTIMATION
Thursday 7 May, 2026
Objectives Conducting pharmacokinetic (PK) studies in paediatric populations presents significant challenges due to physiological vulnerability, sampling limitations [1] and ethical…
Read moreEnrichment, Response Amplification, Separation, and Inclusion: Quantifying Trial Design Trade-offs in SLE with QSP SimPopsâ„¢ Modeling
Thursday 7 May, 2026
Objectives: Routine diagnostic assays (e.g., blood counts, complement, autoantibodies) are standard in the clinical evaluation of systemic lupus erythematosus (SLE)…
Read more